相关实验视频

Updated: Jan 9, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

自然启发的MYC抑制剂破坏了MYC驱动的糖解,并限制了卵巢瘤的生长

Mamta Singh¹, Anubha Yadav¹, Umesh Singh²

¹Amity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Uttar Pradesh, 201313, India.

|November 30, 2025

概括

一个新的小分子,GD-07,有效地准卵巢癌细胞中的c-MYC瘤基因促进体. 这种抑制剂显示出高疗效和广泛的治疗窗口,为癌症治疗提供了一个有希望的新途径.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

MYC瘤基因是许多癌症的关键驱动因素,但它缺乏明确的结合部位阻碍了向疗法的开发.
由于直接向MYC蛋白的挑战,现有的MYC抑制剂在临床应用中受到限制.

研究的目的:

确定和描述一种针对c-MYC促进体的新型小分子抑制剂.
在卵巢癌模型中评估GD-07的疗效和安全性.

主要方法:

化学信息学和分子对接被用来识别GD-07.
核磁共振 (NMR) 谱学被用来确定GD-07与c-MYC G-四重复合体 (G4) 的结合部位.
在卵巢癌细胞系和患者衍生的有机体中进行了体外细胞毒性测定,将GD-07与碳白金进行了比较.

主要成果:

GD-07选择性地与高亲和度的c-MYC G4结构结合,与双链DNA不同.
与卡博普拉丁相比,GD-07在卵巢癌细胞中表现出优异的细胞毒性,对正常细胞的影响最小.
该化合物抑制了MYC表达,降低了葡萄糖代谢和葡萄糖分解,并调高了p53和前位标记物.

结论:

GD-07是一种有前途的类似药物的小分子抑制剂,向c-MYC促进体G4结构.
它的选择性细胞毒性和有利的药物动力学特征表明它对卵巢癌具有显著的治疗潜力.
在患者衍生器官中,GD-07的活性比碳烯更大,这表明其具有很强的临床可转化性.

关键词:

G 四重复式的四重复式骨髓细胞瘤瘤瘤瘤发生在骨髓细胞瘤上癌症的代谢癌症的代谢发现药物的发现.卵巢癌是发生在卵巢的癌症.

更多相关视频

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...

Hormonal Control of the Ovarian Cycle

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...